Diabetic Complications Space Sees Increase in Innovative Therapies, States GBI Research in Topical Report Published at MarketPublishers.com
26 Jul 2016 • by Natalie Aster
LONDON – The prevalence rates of diabetes are on the rise, with this long-term condition presently affecting 10% of adults worldwide and likely become the 7th leading cause of mortality by 2030.
The dearth of absolute therapy for the disease and the difficulty in retaining stable glycemic control, even after adequate treatment have been provided, can lead to a set of complications. The 3 key groups of indications are diabetic nephropathy, diabetic retinopathy, and a range of diabetic neuropathies.
The need for advanced therapeutic agents within diabetic complications is specifically prominent by contrast to other multi-systemic conditions, as the market mainly consists of therapies that treat the condition symptomatically, or, in a best-case scenario, slow the progression of the disease. However, with an increasing understanding of disease pathophysiology in diabetes and its complications, novel targets are being identified and morphed into enhanced, more effective therapeutic options.
The diabetic complications pipeline is composed of 429 products that enclose a slew of targets not presently in use within the marketplace. The upsurge in molecular target diversity implies the strong potential for changes and enhancements in the diabetic complications space. Thus, innovation has been seen within diabetic neuropathy and diabetic retinopathy, with therapies like CBX-129801 and BCN070660, respectively, being currently in development.
Topical study “Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies” drawn up GBI Research presents an all-round market analysis. It reviews the current therapeutic and commercial landscape, considering the disease pathogenesis, diagnosis, prognosis and the available treatment options; examines the structure of the market for each individual diabetic complication, with respect to leading molecule types and targets, limelighting the current unmet needs and enabling a refined understanding of gaps in the present-day market. The study canvasses the pipeline for each specific diabetic complication, stratifying it by development stage, molecule type and target. It assesses the first-in-class products and ranks them according to therapeutic potential, and gives a detailed look at the most promising early-stage targets. Furthermore, the lucrative commercial opportunities in the diabetic complications deals universe are also identified in the study.
More reports by the publisher can be found at GBI Research page.